Dr Lewis Au
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
18 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Retraction note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy (Nature, (2023), 616, 7957, (563-573), 10.1038/s41586-023-05771-9)
DOI: 10.1038/s41586-026-10104-72026
Journal article
Nuclear Imaging in Renal Cell Carcinoma: Current Evidence and Clinical Applications
DOI: 10.3390/cancers180201952025
Journal article
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
DOI: 10.1016/S1470-2045(25)00559-52025
Journal article
Neoadjuvant Pembrolizumab and Stereotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NAPSTER): A Phase II Randomised Clinical Trial
DOI: 10.1016/j.ijrobp.2025.06.11782025
Journal article
2386P A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial
DOI: 10.1016/j.annonc.2025.08.30022025
Journal article
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
DOI: 10.1016/S1470-2045(25)00332-82025
Journal article
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study
DOI: 10.2967/jnumed.124.268639
RECENT SCHOLARLY WORKS
2025
Journal article
Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
DOI: 10.2967/jnumed.124.2686402024
Journal article
Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer
DOI: 10.1038/s41585-024-00913-82024
Journal article
Tissue resident memory (TRM) T cells and dendritic cells form an in situ archetype for improved response to immune checkpoint therapy in metastatic melanoma
DOI: 10.1158/2326-6074.TUMIMM24-A006